Choose SmartSignals Digital Solutions for Non-Small Cell Lung Cancer Clinical Trials Date Published: May 26, 2021 Brochure Signant SmartSignals solutions can help researchers improve oncology treatment and therapies. We’ve configured our electronic clinician outcome assessment (eCOA) solution with pre-validated library instruments and oncology-specific features to best support non-small cell lung cancer (NSCLC) research. This helps your team get started faster and significantly reduce costs. Get details on how Signant helps NSCLC studies: Accelerate startup times Provide a patient-focused approach Simplify the consent process Optimize supplies Cut costs Look inside for our NSCLC study experience and therapeutic area experts. Download Now Share: LinkedInTweet Recommended Resources Video Non-Small Cell Lung Cancer Research Solutions Streamline your non-small cell lung cancer cancer (NSCLC) clinical research cancer with Signant’s electronic solutions and team of experts. With... Watch Now Biotech Better: Solutions for Emerging Biotech/Biopharma Trials Download Now Brochure Article Optimal COA Measurement Strategy in Modern Oncology Trials The inclusion of patient-reported outcomes (PRO) data in oncology medication labeling in the U.S. has been comparatively limited. Recent FDA... Read Now